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Abstract
Background: Birth weight and prematurity are important obstetric outcomes linked to lifelong health. We studied a large
birth cohort to look for evidence of epigenetic involvement in birth outcomes.
Methods: We investigated the association between birth weight, length, placental weight and duration of gestation and
four candidate variants in 1,236 mothers and 1,073 newborns; DNMT1 (rs2162560), DNMT3A (rs734693), DNMT3B (rs2424913)
and DNMT3L (rs7354779). We measured methylation of LINE1 and the imprinted genes, PEG3, SNRPN, and IGF2, in cord
blood.
Results: The minor DNMT3L allele in the baby was associated with higher birth weight (+54 95% CI 10,99 g; p = 0.016), birth
length (+0.23 95% CI 0.04,0.42 cm; p= 0.017), placental weight, (+18 95% CI 3,33 g; p = 0.017), and reduced risk of being in
the lowest birth weight decile (p = 0.018) or requiring neonatal care (p = 0.039). The DNMT3B minor allele in the mother was
associated with an increased risk of prematurity (p = 0.001). Placental size was related to PEG3 (p,0.001) and IGF2 (p,0.001)
methylation. Birth weight was related to LINE1 and IGF2 methylation but only at p = 0.052. The risk of requiring neonatal
treatment was related to LINE1 (p = 0.010) and SNRPN (p = 0.001) methylation. PEG3 methylation was influenced by baby
DNMT3A genotype (p = 0.012) and LINE1 by baby 3B genotype (p = 0.044). Maternal DNMT3L genotype was related to IGF2
methylation in the cord blood but this effect was only seen in carriers of the minor frequency allele (p = 0.050).
Conclusions: The results here suggest that epigenetic processes are linked birth outcome and health in early life. Our
emerging understanding of the role of epigenetics in health and biological function across the lifecourse suggests that
these early epigenetic events could have longer term implications.
Citation: Haggarty P, Hoad G, Horgan GW, Campbell DM (2013) DNA Methyltransferase Candidate Polymorphisms, Imprinting Methylation, and Birth
Outcome. PLoS ONE 8(7): e68896. doi:10.1371/journal.pone.0068896
Editor: Osman El-Maarri, University of Bonn, Institut of experimental hematology and transfusion medicine, Germany
Received November 3, 2011; Accepted June 9, 2013; Published July 26, 2013
Copyright:  2013 Haggarty et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The birth cohort was funded by Food Standards Agency (grant no: N05040). PH and GH acknowledge the support of the Scottish
Government(REERAD). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: p.haggarty@abdn.ac.uk
Introduction
Factors such as birth weight and placental weight are important
indicators of the health of the newborn but they have also been
linked to health and biological function in later life [1–3].
However, the relationships are complex with higher birth weight
being associated with reduced cardiovascular mortality but a
higher risk for certain cancers [2,3] including breast cancer [4].
There are also complex links with socioeconomic position,
employment status and cognition. Lower birth weight and
hospitalisation during childhood are associated with lower
occupational position and adverse changes in cardiometabolic
factors and an increased risk of metabolic syndrome [5]. Cognitive
ability is associated with birth weight [6,7] and intelligence in
youth is associated with all-cause-mortality [8]. Prematurity is also
associated with long term disadvantage and increased risk of
mortality throughout childhood [9].
The nature of these associations and the causal links between
them are not well understood. It has been proposed that
nutritional and other environmental influences in pregnancy
may programme both birth weight and health in later life [1,2].
However, there is a heritable component to birth weight and
length of gestation [9–11] and many of the adult diseases linked to
birth weight [12]. This has led to an alternative hypothesis that
common genetic pathways underpin prenatal growth and adult
health outcomes [3,11,13]. There is now a third category, based
on epigenetics, which opens up the possibility that either or both
explanations may be correct [14–16]. Knowledge of the causal
mechanism is important as it could lead to different strategies to
improve health across the lifecourse.
We set out to look for evidence of epigenetic involvement in
birth outcomes in a large birth cohort. The role of epigenetics in
human complex traits is difficult to study as the epigenome of
readily accessible tissues such as blood may not reflect the
epigenome within the tissues of interest. Perhaps paradoxically,
evidence for the involvement of epigenetic processes may be
obtained from genetic association studies. DNA methylation is
probably the most commonly studied epigenetic phenomenon. We
investigated the association between birth weight, length, placental
weight and duration of gestation and four candidate polymor-
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phisms in genes involved in DNA methylation in mothers and
newborns. Polymorphisms were measured in the four DNA
methyltransferases: DNMT1 (MIM126375); DNMT3A
(MIM602769); DNMT3B (MIM602900); DNMT3L
(MIM606588) in order to provide additional information on
specific epigenetic process.
Recent work suggests that many imprinted genes maintain their
allele specific methylation signal in a wide range of adult somatic
tissues, independent of the absolute levels of expression [17]. We
measured DNA methylation in the imprinted genes – Paternally
expressed gene 3 (PEG3; 19q13; OMIM 601483); Insulin-like
growth factor II (IGF2; 11p15; OMIM 147470); Small nuclear
ribonucleoprotein polypeptide N (SNRPN; 15q12; OMIM
182279) – and the transposable element – Long interspersed
nuclear element 1 (LINE-1; OMIM 151626) in newborn cord
blood and determined the association between these and birth
weight, length, placental weight and duration of gestation.
Materials and Methods
The study was approved by Grampian Research Ethics
Committee and all women in the study gave informed written
consent to take part. Women who met the inclusion criteria were
recruited consecutively. Women who were diabetic, carrying
multiple pregnancies, who conceived as a result of fertility
treatment, or in whom clinical data was not available, were
excluded. Information on each pregnancy was abstracted from
Aberdeen Maternity and Neonatal Databank and the data
anonymised. Low birth weight was defined as the lowest decile
for the standardised birth weight score; this is the birth weight z
score adjusted for gestational age, sex and parity [18]. Deliveries
before 37 weeks gestation were defined as pre-term. Pregnancies in
which the newborn was admitted to the neonatal unit for any
reason were categorised as requiring neonatal treatment.
Variant Selection and Genotyping
Women provided a blood and buccal sample whilst attending
for ultrasound scan in Aberdeen Maternity Hospital and a sample
of cord blood was collected at delivery. The concentration of DNA
was determined by TaqMan RNaseP detection assay (Applied
Biosystems, Warrington, UK) before genotyping. Genotypes were
detected by allelic discrimination assay using TaqManH MGB
probes labelled with 6-FAMTM and VICH on a 7500 Fast real-
time PCR system (Applied Biosystems, Warrington, UK) [19]. We
used the targeted candidate gene/polymorphism approach [20]
which has the advantage of minimising the number of variants
studied and hence reducing the risk of false positive results.
Variants (DNMT1 MIM126375 19p13.3-p13.2; rs2162560;
DNMT3A MIM 602769; 2p23; rs734693; DNMT3B
MIM602900; 20q11.2; rs2424913; DNMT3L MIM606588;
21q22.3; rs7354779) were selected for study on the basis of links
to a phenotype. The DNMT3B variant has been linked to cancer
[21–23] and Downs Syndrome [24]. The DNMT3L variant has
been linked to reproductive function [25,26] and intelligence [27].
The DNMT1 and 3A SNPs were selected on the basis of our own
unpublished observations in relation to cancer and reproduction.
The DNMT3L variant is a nonsynonymous polymorphism
resulting in an amino acid change at codon 278 within the C-
terminal portion of DNMT3L. Such nonsynonymous variations in
the functional domains of the DNMTs are unusual and no non-
synonymous polymorphisms have been detected in the catalytic
domains of DNMT3A/B or DNMT1 in a European population
[28]. Genotyping was carried out by laboratory staff blind to the
birth outcomes. All eligible cases in which DNA was available
were measured and all valid results included in the analysis. Any
incompatible maternal and baby genotypes were excluded.
DNMT results were available in 1,236 mother and 1,073
offspring. The smaller number in the offspring reflected the
practical difficulty of obtaining cord blood from all recruited
pregnancies.
Methylation
We studied methylation in three imprinted genes and one
retrotransposon in genomic DNA extracted from cord blood.
Methylation was measured by pyrosequencing using a PyroMark
MD system (Qiagen, Crawley, UK) after bisulphite conversion of
DNA using Epitect Bisulfite kits (Qiagen, Crawley, UK). Long
interspersed nuclear element 1 (LINE-1; OMIM 151626) is a class
II retroposon which can be transcribed into RNA, reverse
transcribed into cDNA, and then reintegrated as cDNAs into
the genome at a new location. The genome retrotransposon
content varies between individuals but there are over 500,000
LINE-1 copies in the human genome with around 80–100 active
elements [29]. Insulin-like growth factor II (IGF2; 11p15) has been
implicated in fetal growth, imprinting syndromes, Wilms Tumour,
obesity, metabolic syndrome (OMIM 147470). Paternally ex-
pressed gene 3 (PEG3; 19q13) is a regulator of TNF response and
has been implicated in tumour development (OMIM 601483).
Small nuclear ribonucleoprotein polypeptide N (SNRPN; 15q12)
is a bicistronic maternally methylated imprinted gene that encodes
2 polypeptides, the SmN splicing factor, which is involved in RNA
processing, and the SNRPN upstream reading frame (SNURF)
polypeptide, it is associated with Prader-Willi syndrome and
Angelman syndrome, two clinically distinct neurogenetic disorders
(OMIM 182279). Assays were carried out using previously
published primer sets for IGF2 [30], PEG3 [31], and SNRPN
[32] and a commercially available kit for LINE1 (Qiagen,
Crawley, UK). The number of CpG sites was 7 for PEG3, and
4 for SNRPN, IGF2 and LINE1. The methylation level at
adjacent CpG sites was highly correlated therefore an average
methylation level for each gene/region was used in the analysis.
Statistics
Statistical analysis was carried out using STATA/SE version 12
(Stata Corp, College Station, Texas, USA). Comparison of
genotype frequencies in mothers and offspring was tested by a
Pearson Chi-square test. Genotypes were also tested for deviation
from Hardy-Weinberg equilibrium. Regression analysis was
carried out for each variant on the basis of an intermediate
heterozygote effect (homozygote minor frequency.heterozygo-
te.homozygote common). Multiple linear regression was used for
continuous dependent variables (baby weight, placental weight,
baby length, gestational age) and logistic regression for categorical
outcomes (low birth weight, pre-term birth, neonatal treatment),
with adjustment for appropriate covariates (specified in the results
section). Regression results are presented with 95% confidence
intervals and p values.
Results
The mean characteristics of the mothers studied were; age at
delivery 30.5 (SD 5.4) years; height 164 (SD 7) cm; gestational age
at delivery 39 (SD 2) weeks; weight at booking 69 (SD 15) kg. The
birth weight was 3475 (SD 531) g; placental weight 645 (SD 143)
g; crown heel length 50 (SD 2) cm; gestation length 39 (SD 2) wks.
Births before 37 weeks gestation made up 4.3 (95% CI 3.1,5.4) %
of pregnancies and babies requiring neonatal care 15.3 (95% CI
13.3,17.3) %. The lowest birth weight decile, by definition, made
DNMT Polymorphisms, Imprinting and Birth Outcome
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e68896
up 10% of cases. The number of non-Caucasian mothers was
small (n = 38). 15 (95% CI 13, 17) % of the mothers were smokers.
The distribution of genotypes was not significantly different
between mothers and babies (Table 1) and there was no evidence
of significant deviation from Hardy-Weinberg equilibrium. Birth
weight, adjusted for gestational age and sex, was significantly
related to the baby DNMT3L genotype (Table 2). The minor
allele was associated with a dose dependent increase in adjusted
birth weight of 54 (95% CI 10,99) g (p = 0.016). The risk of being
in the lowest decile for standardised birth weight (adjusted for
gestation and baby sex) was also related to the baby DNMT3L
allele (odds ratio = 0.63; 95% CI=0.42,0.92; p = 0.018). The baby
DNMT3L allele was associated with birth length 0.23 (95% CI
0.04,0.42) cm (p= 0.017) and placental weight 18 (95% CI 3,33) g
(p = 0.017) after adjustment for gestational age and baby sex.
The imprinted genes PEG3 and IGF2 were significantly related
to placental size; 6.9 (95% CI 3.6,10.3; p,0.001) g/% change in
methylation for PEG3 and 24.2 (95% CI 26.2, 22.2; p,0.001)
g/% change in methylation for IGF2 (Table 3). There were no
significant relationships between gestational age and baby length
and methylation in any of the regions studied. There was a
borderline significant association between birth weight, adjusted
for gestational age and baby sex and methylation of LINE1 (213.5
95% CI 227.2,0.1; p = 0.052; g/% change in methylation) and
IGF2 (26.1 95% CI 212.2, 20.1; p = 0.052; g/% change in
methylation). Any effect on birth weight appears to span the full
birth weight range as the risk of being in the lowest birth weight
decile was not related to DNA methylation.
The risk of requiring neonatal care after birth was significantly
related to gestational age at delivery and baby sex (Table 4). After
adjustment for gestational age, birth weight, and sex the baby
DNMT3L minor frequency allele was associated with a reduced
risk of requiring neonatal care (odds ratio = 0.73; 95%
CI= 0.54,0.98; p = 0.039). The risk of requiring neonatal treat-
ment was also related to methylation within LINE1 (p= 0.010)
and SNRPN (p= 0.001) (Table 5).
For those outcomes significantly related to birth outcomes the
unadjusted means are shown by baby DNMT3L allele in
Figures 1 and 2. Birth weight and birth length both demon-
strated intermediate heterozygote effects, though for placental
weight the carriers of the minor frequency allele (homozygote and
heterozygote) were associated with the similar placental weights
(Figure 1). Intermediate DNMT3L heterozygote effects were also
observed for the proportions of babies in the lowest decile for birth
weight and the proportion requiring neonatal care (Figure 2).
There was no evidence of an effect of maternal DNMT3L
genotype on any of the outcomes studied.
There were also no significant relationships between maternal
or baby DNMT1, 3A and 3B genotype and birth length or
placental weight. However, mother and baby DNMT3B genotype
was related to the length of gestation (Table 2). The genotype
effect was most significant in the mother where the DNMT3B
minor frequency allele was associated with a small reduction in
gestation length of 1.3 days (p = 0.006) but an almost doubling of
the risk of prematurity (,37 weeks gestation); odds ratio = 1.95;
95% CI= 1.30,2.94; (p = 0.001). For all the variants studied there
was, as expected, significant covariance between maternal and
baby genotype and this appears to explain the baby DNMT3B
genotype association with gestation as only the maternal genotype
remained significantly associated with gestation when both the
maternal and baby DNMT3B genotypes were included in the
regression analysis. The most striking and consistent effect of
genotype was that between DNMT3L and birth outcome but
there was also a separate effect of DNMT3A on birth weight
where the minor allele was associated with a lower birth weight
(Table 2). The effect size was similar to that for DNMT3L (241
95% CI 280, 21 g) but the level of significance was lower
(p = 0.042). There was no evidence of interaction between baby
DNMT3L and maternal DNMT3A genotype in relation to birth
weight.
All significant associations remained significant after adjustment
for smoking. Removal of the non-Caucasian pregnancies made no
significant difference to any of the population genotype frequen-
Table 1. DNMT genotypes and allele frequencies in mothers and babies.
Gene (variant)
DNMT1 (rs2162560) DNMT3A (rs734693) DNMT3B (rs2424913) DNMT3L (rs7354779)
Genotypes
Homozygote common: mother 380 (32.1) 634 (52.4) 357 (29.3) 622 (52.3)
baby 336 (33.2) 536 (51.2) 333 (31.3) 532 (52.3)
Heterozygote: mother 593 (50.0) 474 (39.1) 609 (50.0) 465 (39.1)
baby 492 (48.6) 427 (40.8) 512 (48.2) 422 (41.5)
Homozygote minor: mother 212 (17.9) 103 (8.5) 253 (20.8) 103 (8.7)
baby 185 (18.3) 84 (8.0) 218 (20.5) 63 (6.2)
Total: mother 1,185 (100) 1,211 (100) 1,219 (100) 1,190 (100)
baby 1,013 (100) 1,047 (100) 1,063 (100) 1,017 (100)
Allele frequencies
Common allele: mother 0.57 0.72 0.54 0.72
baby 0.57 0.72 0.55 0.73
Minor allele: mother 0.43 0.28 0.46 0.28
baby 0.43 0.28 0.45 0.27
Genotype frequencies are shown with the percentages in brackets. Allele frequencies are expressed as proportions. All genotypes were in Hardy-Weinberg equilibrium
(Chi-squared test).
doi:10.1371/journal.pone.0068896.t001
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Table 2. Continuous birth outcomes and their relationship to DNMT variants in mothers and babies.
Gene1
DNMT1 DNMT3A DNMT3B DNMT3L
Coefficient
(95% CI)
p
value
Coefficient
(95% CI)
p
value
Coefficient
(95% CI)
p
value
Coefficient
(95% CI)
p
value
Maternal genotype
Birth weight (g)2 3 0.895 241* 0.042 10 0.580 11 0.590
(235, 40) (280, 21) (226, 46) (229, 50)
Crown heel length (cm) 2 20.03 0.744 20.05 0.562 0.04 0.622 0.10 0.227
(20.18, 0.13) (20.22, 0.12) (20.12, 0.19) (20.06, 0.27)
Placental weight (g) 2 1 0.897 210 0.115 1 0.839 6 0.383
(211, 13) (223, 2) (210, 13) (27, 18)
Gestation at delivery (weeks) 3 20.03 0.652 20.03 0.724 20.19** 0.006 0.11 0.128
(20.17, 0.11) (20.17, 0.12) (20.32, 20.05) (20.03, 0.26)
Baby genotype
Birth weight (g) 2 27 0.736 8 0.699 22 0.237 54* 0.016
(246, 32) (234, 51) (215, 61) (10, 99)
Crown heel length (cm) 2 20.03 0.711 0.06 0.521 0.06 0.439 0.23* 0.017
(20.20, 0.14) (20.12, 0.24) (20.10, 0.22) (0.04, 0.42)
Placental weight (g) 2 0.3 0.968 25 0.482 3 0.599 18* 0.017
(212, 13) (219, 9) (29, 16) (3, 33)
Gestation at delivery (weeks) 3 0.02 0.786 20.0007 0.992 20.14* 0.035 0.01 0.943
(20.12, 0.15) (20.15, 0.15) (20.27, 20.01) (20.15, 0.16)
1Variants specified in Table 1. Linear regression analysis based on all three genotype frequencies (homozygote minor frequency.heterozygote.homozygote common)
adjusted for baby sex, and gestational age 2 or baby sex alone 3.
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0068896.t002
Table 3. Continuous birth outcomes and their relationship to to LINE1, PEG3, SNRPN and IGF2 methylation in cord blood.
Methylation status
LINE 1 PEG3 SNRPN IGF2
Coefficient
(95% CI)
P
Value
Coefficient
(95% CI)
p
value
Coefficient
(95% CI)
p
value
Coefficient
(95% CI)
p
value
Birth weight
(g) 1
213.546 0.052 3.032 0.575 1.901 0.602 26.084 0.052
(227.182,0.089) (27.562,13.626) (25.243,9.045) (212.227,0.059)
Crown heel
length (cm) 1
20.0291 0.326 0.0149 0.512 20.0048 0.752 20.0161 0.222
(20.0871,0.0289) (20.0297,0.0595) (20.0348,0.0252) (20.0420,0.00976)
Placental
weight (g) 1
20.684 0.763 6.948*** ,0.001 0.526 0.655 24.225*** ,0.001
(25.128,3.760) (3.576,10.319) (21.782,2.835) (26.218, 22.232)
Gestation at
delivery
(weeks) 2
20.00718 0.747 0.0102 0.552 0.0119 0.301 20.0126 0.208
(20.0508,0.0364) (20.0235,0.0440) (20.0107,0.0346) (20.0321,0.0070)
Linear regression analysis of DNA methylation on birth parameters. Analyses were adjusted for baby sex, and gestational age 1 or baby sex alone 2.
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0068896.t003
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cies and all the significant DNMT3L associations remained
significant after exclusion of non-Caucasian mothers from the
analysis. The effect of DNMT3A genotype on birth weight and
DNMT3B on length of gestation were the least significant before
the exclusion and just below significance following the reduction in
numbers; though the stronger DNMT3B effect on risk of
prematurity remained highly significant (p = 0.002) after exclusion
of the non-Caucasian pregnancies.
Simple Bonferonni correction results in borderline significance
for the DNMT3L effects but we believe that this adjustment is too
conservative. It does not take account of the fact that the genotype
was linked to multiple birth outcomes (birth weight, risk of low
birth weight, birth length, placental weight, risk of requiring
neonatal care). Nor does it take into account the additional
biological plausibility conferred by the observation of an interme-
diate heterozygote effect for all but one of these outcomes.
There were also significant relationships between DNMT
genotype and level of methylation in cord blood DNA even after
exclusion of non-Caucasians. In the full additive model the baby
genotype for DNMT3A was related to PEG3 methylation (0.4;
95% CI= 0.1,0.7% methylation; p = 0.012) and the baby 3B
genotype to LINE1 methylation (20.2; 95% CI=20.4, 20.01%
methylation; p = 0.044). The maternal DNMT3L genotype was
also related to IGF2 methylation in the cord blood but this effect
was only seen in carriers of the minor frequency allele compared to
non-carriers (20.7; 95% CI=21.3, 20.0001% methylation;
p = 0.050).
Discussion
Babies carrying the DNMT3L minor allele were heavier at
birth. They were also longer and their placentas were heavier.
These associations remained significant after adjustment for
gestational age and sex. Compared to babies homozygous for
the common allele, those homozygous for the minor frequency
allele were a third as likely to be in the lowest decile for birth
weight and there was a clear allele dose response (homozygote
minor frequency.heterozygote.homozygote common). An in-
termediate effect of the heterozygote is not required to establish a
link between a gene variant and health outcome but such an effect
provides additional assurance that the association is likely to be
biologically significant. There was also an association between
maternal DNMT3A genotype and birth weight but the signifi-
cance level was lower than for DNMT3L and there was no
Table 4. Categorical birth outcomes and their relationship to DNMT variants in babies.
Gene1
DNMT1 DNMT3A DNMT3B DNMT3L
Odds ratio
(95% CI)
p
value
Odds ratio
(95% CI)
p
value
Odds ratio
(95% CI)
p
value
Coefficient
(95% CI)
p
value
Risk of low birth weight (lowest decile) 2 1.19 0.266 0.76 0.125 1.12 0.443 0.63* 0.018
(0.88, 1.61) (0.54, 1.08) (0.84, 1.49) (0.42, 0.92)
Risk of need for neonatal treatment 3 0.97 0.837 1.07 0.622 0.87 0.279 0.73* 0.039
(0.76, 1.25) (0.82, 1.40) (0.68, 1.12) (0.54, 0.98)
1Variants specified in Table 1. Logistic regression analysis based on all three genotype frequencies (homozygote minor frequency.heterozygote.homozygote
common). The standardised birth weight is already adjusted for gestational age and baby sex 2; the risk of requiring neonatal treatment was adjusted for gestational
age, baby sex and baby weight 3.
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0068896.t004
Table 5. Categorical birth outcomes and their relationship to LINE1, PEG3, SNRPN and IGF2 methylation in cord blood.
Methylation status
LINE 1 PEG3 SNRPN IGF2
Odds ratio
(95% CI)
p
value
Odds ratio
(95% CI)
p
value
Odds ratio
(95% CI)
p
value
Coefficient
(95% CI)
p
value
Risk of low birth weight
(lowest decile) 1
1.030 0.580 0.951 0.232 1.017 0.484 1.041 0.096
(0.929,1.141) (0.875,1.033) (0.970,1.066) (0.993,1.092)
Risk of need for neonatal
treatment 2
0.893* 0.010 0.939 0.082 0.902** 0.001 0.989 0.566
(0.818,0.974) (0.874,1.008) (0.851,0.957) (0.951,1.028)
Logistic regression analysis. The standardised birth weight is already adjusted for gestational age and baby sex 1; the risk of requiring neonatal treatment was adjusted
for gestational age, baby sex and baby weight 2.
*p,0.05,
**p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0068896.t005
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corresponding effect on birth length or placental weight. The
DNMT3B variant in the mother was associated with a small effect
on the average length of gestation but the effect on prematurity
(birth before 37 weeks gestation) was more substantial, with the
minor frequency allele being associated with an approximate
doubling of the risk of prematurity.
The most striking effect was observed in relation to the
DNMT3L variant in the baby. The fact that the association was
observed for both birth weight and length suggests that the
genotype is linked to body scaling rather than a specific body
component such as fat mass. The genetic effect on birth weight
was relatively large, with each addition of the 3L minor frequency
allele accounting for an additional 54 g in birth weight. This is
similar in magnitude to the influence on birth weight of
environmental tobacco smoke during pregnancy [33]. However,
the DNMT3L association is unlikely to be of value in the clinical
management of pregnancy, not least because the predictive
genotype resides in the baby’s DNA which is not easy to sample
safely. The main value of this finding is that it points to specific
biological processes which are worthy of further study in relation
to birth outcome, and possibly also longer term health and
biological function.
The significant effects reported here were all observed in the
DNMT3 family of methyltransferases. The DNMT3L variant
results in an amino acid change at codon 278 but the effect of this
change has yet to be elucidated. DNMT3A, 3B and 3L are central
to the process of de novo methylation [34–36] and histone
modification through interaction with histone deacetylase [37,38].
Figure 1. Birth weight, placental weight and birth length by baby DNMT3L genotype. Raw data unadjusted for any other variable. Error
bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0068896.g001
Figure 2. Proportion of babies in lowest standardised birth weight decile and the proportion requiring neonatal treatment by baby
DNMT3L genotype. Raw data unadjusted for any other variable. Error bars represent 95% confidence intervals.
doi:10.1371/journal.pone.0068896.g002
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The DNMT3 family is also essential for imprinting [35,39]. All are
expressed in oocytes coincident with imprinting methylation [40]
and Dnmt3L is highly expressed in the chorion which contains the
trophoblast stem cells [41]. Animal knockouts of the Dnmt3 family
result in loss of imprinting, biallelic expression of imprinted genes,
and altered methylation at non imprinted loci [34–36] but there
are species differences in epigenetic regulation and the functional
effects of the DNMT3 family in humans are not fully understood.
One way to address this in humans is to look at the effect on
methylation of genotype within these genes. In this cohort baby
DNMT3A genotype was related to PEG3 methylation and
DNMT3B genotype to LINE1 methylation. DNMT3L genotype
was also related to IGF2 methylation. However, in this case it was
the maternal genotype that was important, possibly indicating that
this variant has its effect at an earlier stage of development. The
timing of imprinting in relation to development varies depending
on the region [42].
Imprinted genes have a central role in controlling the fetal
demand for nutrients and the placental supply and IGF2 in
particular is thought to be important in modulating fetal nutrient
transport [43]. In this cohort offspring IGF2 and PEG3
methylation were strongly related to placental weight and IGF2
was borderline significantly associated with birth weight. Trans-
posable elements that flank imprinted genes are thought to be
important in setting and maintaining the imprint [44,45] and they
also demonstrate parent-of-origin effects characteristic of imprint-
ing [46]. Transposable elements such as LINE1 have the ability to
move around the genome and cause abnormal function and
disease if inserted into an important conserved sequence [29,47],
and this process is inhibited by methylation [29]. There is a report
of a biphasic relationship between LINE1 methylation and birth
weight in a smaller study [48]. This was not observed here though
we did observe a linear association between birth weight and
LINE1 methylation at p = 0.052.
There was evidence that epigenetic processes were associated
with general health in the offspring at the start of life,
independently of the links to birth weight and placental weight.
DNMT3L genotype in the baby and methylation within LINE1
and the imprinted gene SNRPN were linked to the health of the
newborn (risk of requiring neonatal treatment) after adjustment for
birth weight, sex and gestational age.
In terms of later health, loss of imprinting, of IGF2 in particular,
is a common characteristic of many cancer types including; breast,
lung, colon, liver, ovary but it has been proposed that more subtle
epigenetic changes could play a seminal role in the earliest steps in
cancer initiation [49–51] and variation in imprinting occurs in
normal tissue of cancer patients or those at increased risk of the
disease [49]. The risk of breast cancer increases in a graded way
with increasing birth weight [4]. Lower levels of IGF2 methylation
have been related to increased cancer risk [52] and IGF2
methylation in this study was associated with a significantly lower
placental weight and a borderline significant reduction in birth
weight. Fetal growth and brain function are the two main health
outcomes associated with the process of imprinting [53–55]. Birth
weight is positively associated with intelligence [6,7] and the same
minor DNMT3L allele linked here to higher birth weight has also
been associated with higher childhood intelligence [27].
The pathways of causality underpinning the epidemiological
observations linking early life events and birth outcome to health
and biological function throughout life are not well understood.
The results here suggest that epigenetic processes are linked to
birth outcome and health in early life. The epigenetic links to birth
outcome are consistent with some of the known epigenetic
associations with later health and biological function. Our
emerging understanding of the role of epigenetics in health and
biological function across the lifecourse suggests that early
epigenetic events could have longer term implications.
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